Can we prevent BRCA1-associated breast cancer by RANKL inhibition?

BRCA1 mutation carriers face a high lifetime risk of breast cancer, estimated at 60 % compared to 10 % in the general population. BRCA1 breast cancers typically have an aggressive course (i.e., high-grade, triple-negative) and are associated with a poor prognosis. At present, primary prevention is l...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2017, Vol.161 (1), p.11-16
Hauptverfasser:	Kotsopoulos, Joanne, Singer, Christian, Narod, Steven A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers BRCA1 Protein - genetics BRCA1 Protein - metabolism Breast cancer Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - prevention & control Cancer genetics Cancer prevention Cancer research Cancer therapies Cell Transformation, Neoplastic - genetics Cell Transformation, Neoplastic - metabolism Chemoprevention - methods Comparative analysis Disease Management Disease prevention Disease susceptibility Female Gene mutation Heterozygote Humans Medicine Medicine & Public Health Monoclonal antibodies Mutation Oncology Osteoprotegerin - genetics Osteoprotegerin - metabolism Prevention Progesterone Progesterone - metabolism Prognosis RANK Ligand - antagonists & inhibitors RANK Ligand - genetics RANK Ligand - metabolism Receptor Activator of Nuclear Factor-kappa B - genetics Receptor Activator of Nuclear Factor-kappa B - metabolism Review Risk factors Signal Transduction - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!